Our results suggest that the balance between CD8+ and Foxp3+ cells in the tumor microenvironment acts as a predictor for GBC patient survival, a situation that allows speculating that boosting natural antitumor immune responses through immunotherapy could represent a possible adjuvant treatment for GBC patients. Here, CD8A is linked to neoplasm.